Vivisum Partners

A variety of factors are considered when healthcare providers (HCPs) speak upon which type 2 diabetes treatments in the clinical pipeline may be more disruptive and why.

Prescribing patterns come from a variety of factors for HCPs, but some are more important than others in the multiple sclerosis marketplace.

While healthcare providers are more familiar with multiple sclerosis therapies such as Evobrutinib, Ocrevus, and Kesimpta, there is a lot of new buzz and anticipation surrounding new MS drug treatments, according to newly published data by market...

The two key factors that neurologists consider when prescribing multiple sclerosis treatments are the MS patient's disease severity, as well as their history with previous MS medications, according to new insights published by market research agency...

Vivisum Partners, LLC has just published new data on how healthcare providers (HCP) determine the best MS treatment to prescribe to their patients.

Despite its strong efficacy, Remicade is facing increased competition from newer drugs and the prospect of pipeline drugs set to launch in the coming years.

Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners.

New research into ulcerative colitis pipeline drugs found that US gastroenterologists who treat irritable bowel disease (IBD) have low awareness of some developing therapies.

Newly published research found that several new ulcerative colitis drugs currently in development are providing excitement among gastroenterologists eager to add additional medicines to their current treatment options.